Ascendis Pharma (NasdaqGS:ASND) has just posted its Q1 2026 numbers, with revenue of €246.6 million and basic EPS of €10.2, alongside trailing twelve month revenue of €865.8 million and basic EPS of €8.12. Over the past year, revenue has moved from €363.6 million in Q4 2024 to €865.8 million on a trailing basis, while basic EPS has shifted from a trailing loss of €6.53 to positive €8.12. This sets up a quarter where reported profitability and revenue scale give investors a clearer view of how margins are shaping the story.

See our full analysis for Ascendis Pharma.

With the headline figures in place, the next step is to see how these results line up with the dominant bullish and cautious narratives around Ascendis Pharma, highlighting where the numbers support the story and where they push back.

Profit swing with €495.9 million TTM net income

• On a trailing twelve month view, net income moved from a loss of €378.1 million in Q4 2024 to a profit of €495.9 million in Q1 2026, with basic EPS over that period shifting from a loss of €6.53 to a profit of €8.12.
• Bears point out that the latest Q1 2026 net income of €629.3 million and TTM profit of €495.9 million come alongside a high level of non cash earnings and operating cash flow that does not fully cover debt, which fits their concern that headline profitability may not translate into equally strong cash generation.
  • Critics highlight that the company only recently turned profitable in the last year, so the move from a TTM loss of €228.0 million in Q4 2025 to a TTM profit of €495.9 million in Q1 2026 could still include items that make earnings less repeatable.
  • The same data set that shows this profit swing also flags weak coverage of debt by operating cash flow, so bears see the strong EPS and net income numbers as something to cross check carefully against future cash flow statements.

Skeptics argue this kind of rapid profit shift can be fragile, especially when cash flows lag the income statement. It can therefore help to understand the full cautious case before deciding how much weight to put on the latest numbers 🐻 Ascendis Pharma Bear Case.

€865.8 million TTM revenue and growth forecasts tested

• Trailing twelve month revenue reached €865.8 million by Q1 2026 compared with €363.6 million at Q4 2024, while the analysis data cites expected revenue growth of about 25% per year and earnings growth around 28.7% per year, alongside a 5 year earnings growth rate of 17.7% per year.
• The bullish narrative leans on these high growth figures, arguing that broader adoption of products like YORVIPATH and SKYTROFA and expansion into new indications can support recurring revenue and higher margins, and the move from a TTM loss of €378.1 million in Q4 2024 to a TTM profit of €495.9 million in Q1 2026 heavily supports that growth story on the income statement.
  • Supporters also point to management’s aspiration for around €500 million in operating cash flow in 2026 and at least €5b in annual product revenue by 2030 as a framework that lines up with the strong revenue trend from €368.7 million TTM in Q1 2025 to €865.8 million TTM in Q1 2026.
  • What stands out is that while the model data show these robust growth expectations, the same risk summary still flags high non cash earnings and limited debt coverage by operating cash flow, which is a key area bulls need to watch to see if the growth story is backed by cash over time.

If you are weighing those growth forecasts against the latest reported figures, it can help to see how bullish investors connect the product pipeline and revenue ambitions to the profit swing just reported 🐂 Ascendis Pharma Bull Case.

P/E of 26.1x vs DCF fair value of €829.64

• The stock trades on a trailing P/E of 26.1x compared with 17.8x for the US Biotechs industry and 12.6x for peers, while the model data point to a DCF fair value of €829.64 against a current share price of €246.14 and an allowed analyst price target of €293.94.
• Consensus style analysis in the data suggests the stock is trading roughly 70.3% below that DCF fair value, which supports a valuation gap story, yet the combination of a higher than peer P/E, high non cash earnings and weak debt coverage by operating cash flow gives a more mixed read on how much of that gap investors may be comfortable with until cash flows better match the income statement.
  • Supporters of the growth and valuation gap narrative point to the shift from a TTM loss of €228.0 million in Q4 2025 to a TTM profit of €495.9 million in Q1 2026 as evidence that profitability has already moved in the direction implied by those models.
  • At the same time, the risk summary flags that shares are highly illiquid, so any re rating from €246.14 toward either the €293.94 analyst target or the much higher DCF fair value could involve sharper price moves and wider trading spreads than in more liquid stocks.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ascendis Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both finding support in these numbers, it makes sense to move quickly, review the figures yourself and decide where you stand by weighing the 3 key rewards and 3 important warning signs.

See What Else Is Out There

Despite the profit swing and strong earnings figures, Ascendis Pharma still shows weak coverage of debt by operating cash flow and high non cash earnings that complicate the quality of profits.

If you want stocks where reported earnings are more closely backed by cash, check out the solid balance sheet and fundamentals stocks screener (44 results) today and compare alternatives side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.